Lytenava is a monoclonal antibody commercialized by Outlook Therapeutics, with a leading Pre-Registration program in Wet (Neovascular / Exudative) Macular Degeneration. According to Globaldata, it is involved in 7 clinical trials, of which 3 were completed, 1 is ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Lytenava’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Lytenava is expected to reach an annual total of $1.03 bn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Bevacizumab-vikg is under development for the treatment of wet age related macular degeneration, diabetic macular edema, branch retinal vein occlusion and other retinal diseases. The drug candidate is a monoclonal antibody developed based on Biosymphony platform. It is administered through intravitreal route in the form of solution. It acts by targeting vascular endothelial growth factor A (VEGFA).
Outlook Therapeutics Overview
Outlook Therapeutics is a biopharmaceutical company. It develops, manufactures, and commercializes biosimilar products in the areas of ophthalmology. The company pipeline product includes ONS-5010 Lytenava, Repackaged Bevacizumab, Ophthalmic anti vegf among others. The company is investigating its lead product candidate, ONS-5010 an ophthalmic formulation of bevacizumab-VIKG intended to treat wet age-related macular degeneration (AMD), diabetic macular edema (DME), branch retinal vein occlusion (BRVO) and other retinal diseases. It works in collaboration with biotechnology and pharmaceutical companies to develop its products. Outlook Therapeutics is headquartered in Cranbury, New Jersey, the US.
The operating loss of the company was US$64.1 million in FY2022, compared to an operating loss of US$51.7 million in FY2021. The net loss of the company was US$66.1 million in FY2022, compared to a net loss of US$53.2 million in FY2021.
For a complete picture of Lytenava’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.